Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture

Type: Plenary Session

Time: Sunday June 2, 1:00 PM to 4:00 PM

Location: Hall B1

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Sub-category:
Advanced Disease

Category:
Genitourinary (Prostate) Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
LBA2

Citation:
J Clin Oncol 37, 2019 (suppl; abstr LBA2)

Author(s): Christopher Sweeney, Andrew James Martin, Robert Richard Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Kaur Sandhu, M. Neil Reaume, David William Pook, Francis Parnis, Scott A. North, Ray McDermott, John McCaffrey, Gavin M. Marx, Nicola Jane Lawrence, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Ian D. Davis; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Central West Cancer Services, Orange, Australia; Royal Cornwall Hospital, Truro, United Kingdom; RAH Cancer Centre, Adelaide, Australia; Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia; Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia; University of Adelaide, Adelaide, Australia; University of Alberta Cross Cancer Institute, Edmonton, AB, Canada; Adelaide and Meath Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; University of Sydney Adventist Hospital, Sydney, Australia; Auckland City Hospital, Auckland, New Zealand; Sydney Cancer Centre, Sydney, Australia; Monash University, Clayton, Australia; Guy’s, King’s and St. Thomas’ Hospitals, and Sarah Cannon Research Institute, London, United Kingdom; BC Cancer, Vancouver, BC, Canada; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia; Monash University Eastern Health Clinical School, Melbourne, Australia

Abstract Disclosures

Abstract:

Background: Testosterone suppression (TS) is the backbone of treatment for mHSPC. OS is improved by the addition of early docetaxel (DOC) or abiraterone to TS. ENZAMET assessed the effects of enzalutamide (ENZA), a potent androgen receptor (AR) inhibitor, versus a nonsteroidal anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide) in addition to SOC (TS with or without DOC) in mHSPC. Methods: Men with mHSPC were randomly assigned 1:1 to receive TS plus either ENZA or NSAA. Randomization was stratified by: volume of disease (high vs low, according to CHAARTED); planned early DOC; planned anti-resorptive therapy, comorbidity score (ACE-27), and study site. The primary endpoint was overall survival. Accrual of 1100 men provided 80% power to detect a 25% reduction in the hazard of death (HR 0.75) with up to 4 interim analyses (IA), the first planned to occur after 235 deaths (50% of total information with a critical p-value threshold <0.0031 by the Lan-DeMets alpha-spending approach with O’Brien-Fleming type shape). Subgroup analyses to assess possible modulation of the treatment effect were specified a priori and included planned early docetaxel (yes vs no) and volume of disease (high vs low). Results: We randomly assigned 1125 patients from 31MAR14 to 24MAR17. The treatment groups were well balanced for all important baseline factors. Criteria for early reporting were met at the first IA (28FEB2019) after a median follow-up of 33 months. Overall survival was prolonged by ENZA (see below). At 3 years, 36% NSAA vs 64% ENZA were still on their assigned study treatment. Serious adverse events (regardless of attribution) within 30 days of study treatment occurred in 42% ENZA vs 34% NSAA, commensurate with the different durations of study treatment. Conclusions: ENZA significantly improved OS when added to SOC in mHSPC. The benefits appeared lower in those planned to receive early DOC. Results of analyses with updated follow-up triggered by this IA will be presented. Clinical trial information: NCT02446405

Group [N]HR (95% CI)NSAA
3yOS%
ENZA
3yOS%
All pts [1125]0.66 (0.51-0.86), p = 0.00167279
High volume disease [596]0.74 (0.55-1.01)6371
Low volume disease [529]0.48 (0.28-0.80)8289
No planned early DOC [622]0.51 (0.36 to 0.73)7083
Planned early DOC [503]0.91 (0.62 to 1.35)7473

 
Other Abstracts in this Sub-Category:

 

1. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 5000 First Author: Karim Fizazi
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

2. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).

Meeting: 2019 ASCO Annual Meeting Abstract No: 5001 First Author: Christian Carrie
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

3. PSMA heterogeneity and DNA repair defects in prostate cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5002 First Author: Alec Paschalis
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

More...